|Classification and external resources|
Kikuchi disease or Kikuchi-Fujimoto disease was described in 1972 in Japan. It is also known as histiocytic necrotizing lymphadenitis, Kikuchi necrotizing lymphadenitis, phagocytic necrotizing lymphadenitis, subacute necrotizing lymphadenitis, and necrotizing lymphadenitis.
It was first described by Dr Masahiro Kikuchi (1935–2012) in 1972 and independently by Y. Fujimoto.
Kikuchi-Fujimoto disease (KFD) is a rare, self-limiting disorder that typically affects the cervical lymph nodes. Recognition of this condition is crucial, especially because it can easily be mistaken for tuberculosis, lymphoma, or even adenocarcinoma. Awareness of this disorder helps prevent misdiagnosis and inappropriate treatment.
Kikuchi's disease is a very rare disease mainly seen in Japan. Isolated cases are reported in North America, Europe, and Asia. It is mainly a disease of young adults (20–30 years), with a slight bias towards females. The cause of this disease is not known, although infectious and autoimmune etiologies have been proposed. The course of the disease is generally benign and self-limiting. Lymphadenopathy most often resolves over several weeks to six months. Recurrence rate is about 3%. Mortality is extremely rare and usually due to hepatic, respiratory, or cardiac failure.
Some studies have suggested a genetic predisposition to the proposed autoimmune response. Several infectious candidates have been associated with Kikuchi disease.
Many theories exist about the etiology of KFD. Microbial/viral or autoimmune causes have been suggested. Mycobacterium szulgai and Yersinia and Toxoplasma species have been implicated. More recently, growing evidence suggests a role for Epstein-Barr virus, as well as other viruses (HHV6, HHV8, parvovirus B19, HIV and HTLV-1) in the pathogenesis of KFD. However, many independent studies have failed to identify the presence of these infectious agents in cases of Kikuchi lymphadenopathy. In addition, serologic tests including antibodies to a host of viruses have consistently proven noncontributory and no viral particles have been identified ultrastructurally. KFD is now proposed to be a nonspecific hyperimmune reaction to a variety of infectious, chemical, physical, and neoplastic agents. Other autoimmune conditions and manifestations such as antiphospholipid syndrome, polymyositis, systemic juvenile idiopathic arthritis, bilateral uveitis, arthritis and cutaneous necrotizing vasculitis have been linked to KFD. KFD may represent an exuberant T-cell-mediated immune response in a genetically susceptible individual to a variety of nonspecific stimuli.
Human leukocyte antigen class II genes are more frequent in patients with Kikuchi disease, suggesting a genetic predisposition to the proposed autoimmune response.
The signs and symptoms of Kikuchi disease are fever, lymphadenopathy, skin rashes, and headache. Rarely, hepatosplenomegaly and nervous system involvement resembling meningitis are seen. Often a bout of extreme fatigue can occur - often taking hold during latter parts of the day and the patient can be more prone to fatigue from exercise. Differential diagnosis includes systemic lupus erythematosus (SLE), disseminated tuberculosis, lymphoma, sarcoidosis, and viral lymphadenitis. Clinical findings sometimes may include positive results for IgM/IgG/IgA antibodies.
For other causes of lymph node enlargement, see lymphadenopathy.
It is diagnosed by lymph node excision biopsy.
Kikuchi disease is a self-limiting illness which has symptoms which may overlap with Hodgkin's lymphoma leading to misdiagnosis in some patients.
No specific cure is known. Treatment is largely supportive. NSAIDs are indicated for tender lymph nodes and fever, and corticosteroids are useful in severe extranodal or generalized disease.
Symptomatic measures aimed at relieving the distressing local and systemic complaints have been described as the main line of management of KFD. Analgesics, antipyretics, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids have been used. If the clinical course is more severe, with multiple flares of bulky cervical lymphadenopathy and fever, then a low-dose corticosteroid treatment has been suggested.
- Rammohan A, Cherukuri SD, Manimaran AB, Manohar RR, Naidu RM (June 2012). "Kikuchi-Fujimoto Disease: A Sheep in Wolf's Clothing". J Otolaryngol Head Neck Surg. 41 (3): 222–226. PMID 22762705.
- Kaushik V, Malik TH, Bishop PW, Jones PH (June 2004). "Histiocytic necrotising lymphadenitis (Kikuchi's disease): a rare cause of cervical lymphadenopathy". Surgeon. 2 (3): 179–82. doi:10.1016/s1479-666x(04)80084-2. PMID 15570824.
- Bosch X, Guilabert A (2006). "Kikuchi-Fujimoto disease". Orphanet J Rare Dis. 1: 18. doi:10.1186/1750-1172-1-18. PMC . PMID 16722618.
- Bosch X, Guilabert A, Miquel R, Campo E (July 2004). "Enigmatic Kikuchi-Fujimoto disease: a comprehensive review". Am. J. Clin. Pathol. 122 (1): 141–52. doi:10.1309/YF08-1L4T-KYWV-YVPQ. PMID 15272543.
- Kikuchi M. Lymphadenitis showing focal reticulum cell hyperplasia with nuclear debris and phagocytes. Acta Hematol Jpn 1972;35:379–80.
- Atwater AR, Longley BJ, Aughenbaugh WD (July 2008). "Kikuchi's disease: case report and systematic review of cutaneous and histopathologic presentations". J. Am. Acad. Dermatol. 59 (1): 130–6. doi:10.1016/j.jaad.2008.03.012. PMID 18462833.
- Rosado, F. G.; Tang, Y. W.; Hasserjian, R. P.; McClain, C. M.; Wang, B; Mosse, C. A. (2013). "Kikuchi-Fujimoto lymphadenitis: Role of parvovirus B-19, Epstein-Barr virus, human herpesvirus 6, and human herpesvirus 8". Human Pathology. 44 (2): 255–9. doi:10.1016/j.humpath.2012.05.016. PMID 22939574.